Analysis of the state of medical and pharmaceutical care provided to cancer patients under the conditions of the healthcare system reform and martial law in the country
DOI:
https://doi.org/10.24959/sphhcj.25.356Keywords:
state provision of medicines to patients; cancer patients; healthcare system; pharmaceutical provision of the population; pharmaceutical care.Abstract
Organizing the provision of effective and affordable medical and pharmaceutical care to cancer patients is an important task in the development of national healthcare systems in any country.
Aim: to analyze the state of medical and pharmaceutical care provided to cancer patients under the conditions of reforming the healthcare system and martial law in the country.
Materials and methods. Historical, analytical-comparative, graphic, logical, organizational-economic, mathematical-statistical methods of analysis were used. Data from special literature, analytical materials presented on the website of the Ministry of Health and the National Health Service of Ukraine were studied.
Results and discussion. It was found that in 2025, compared to 2024, the amounts of contracts concluded in Ukraine increased (by 5.5 % in chemotherapy and 7.27 % in radiology). It was proven that in the structure of contracts for servicing cancer patients in 2025, the dominant positions were occupied by healthcare institutions of municipal ownership (90.8 % – chemotherapy and 84.47 % – radiology). There was an uneven distribution of the number and amounts of contracts by regions of the country according to data of 2025. The highest values of these indicators were in the city of Kyiv, and the lowest in the Luhansk and Cherkasy regions; 17 regions of the country signed only one contract for radiological treatment and support of cancer patients. On average, one contract for the provision of chemotherapy services accounted for 24.39 million UAH, and for radiological treatment – 72.07 million UAH. In the case of chemotherapy, the conditional cost of one contract ranged from 7.17 million (Donetsk region) to 88.44 million UAH (Vinnytsia region), and for radiological treatment – from 21.27 million UAH (Kherson region) to 142.87 million UAH (Vinnytsia region). Under contracts for chemotherapy in 2024, compared to 2022, the amounts of contracts concluded increased by 18.78 % and the actual payment for services by 19.17 %, while for radiological treatment by 15.36 % and 18.99 %, respectively. It was determined that in 2023 the state purchased medicines for cancer patients in the amount of 2,136,971.5 thousand UAH, and in 2024 there was a significant decrease in this indicator (-9.36 %) to 1936975.2 thousand UAH. In the future, the state plans to increase spending on meeting the needs of cancer patients in these drugs.
Conclusions. The resource support of the process of providing medical and pharmaceutical care to cancer patients in Ukraine has been studied. The presence of regional features of the development of this process, as well as positive trends in the increase of the amounts of contracts concluded and payment for the cost of providing care to cancer patients in Ukraine during 2022-2024, has been proven.
References
Incidence, Both sexes, in 2022. All cancers. (2022). International Agency for Research on Cancer. WHO. https://gco.iarc.who.int/today/en/dataviz/tables?mode=population
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 74(3), 229–263. http://doi.org/10.3322/caac.21834.Epub 2024 Apr 4
Kim, J., Harper, A., McCormack, V., Sung, H., Houssami, N., Morgan, E., Mutebi, M., Garvey, G., Soerjomataram, I., & Fidler-Benaoudia, M. M. (2025). Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature Medicine, 31, 1154–1162. https://www.nature.com/articles/s41591-025-03502-3
Natsionalnyi kantser-reiestr Ukrainy: stan bazy danykh na pochatku 2025 roku. http://www.ncru.inf.ua/publications/ucr_db_today.pdf
Fedorenko, Z. P., Goulak, L. O., Gorokh, Y. L., Ryzhov, A. Y., & Soumkina, O. V. Сancer in Ukraine 2022-2023. Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine, 25. http://www.ncru.inf.ua/publications/BULL_25/index.htm
Medychna reforma. Uryadovyy portal. https://www.kmu.gov.ua/reformi/rozvitok-lyudskogo-kapitalu/reforma-sistemi-ohoroni-zdorovya
Analiz zakupivel cherez mizhnarodni orhanizatsiy. (2017, Sichen 30). Shchotyzhnevyk “Apteka”, 12–13. https://www.apteka.ua/article/399472
Kozhukhov, S., Dovganych, N., Smolanka, I., Kryachok, I., & Kovalyov, O. (2022). Cancer and War in Ukraine. JACC CardioOncol, 4(2), 279–282. http://doi.org/10.1016/j.jaccao.2022.04.001
Mendrik, O. A., & Zaliska, O. M. (2012). Otsinka farmakoekonomichnykh aspektiv likuvannia khronichnoi limfotsytarnoi leikemii v Ukraini. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 23(3), 62–67. file:///C:/Users/User/Downloads/Uezyaf_2012_3_11.pdf
Mendrik, O. A. (2013). Farmakoekonomichni doslidzhennia likarskykh zasobiv, yaki vykorystovuiutsia v onkohematolohii [Avtoref. dys. kand. farmatsevt. nauk, Lvivskyi natsionalnyi medychnyi universytet imeni Danyla Halytskoho].
Matushchak, M. R., & Panfilova, H. L. (2023). Farmaekonomichna otsinka ratsionalnosti zastosuvannia skhem khimioterapii, shcho mistiat imunoterapevtychni preparaty, u likuvanni klasychnoi limfomy Khodzhkina. Farmatsevtychnyy zhurnal, 78(3), 68–81.
Mishchenko, O., Adonkina, V., Tkachova, O., Ulanova, V., Kalko, K., Pyliuha, L., & Greshko Iu. (2019). The Results of the Clinical and Economic Assessment of Drugs Prescriptions to patients with Breast Cancer in the Ukrainian Health Care Institution. Research Journal of Pharmacy and Technology, 12(7), 3307–3312. https://doi.org/10.5958/0974-360X.2019.00557.2
Mishchenko, O. Ya., Greshko, Yu. I., Aristov, M. A., Adonkina, V. Yu., & Ostashko, V. F. (2021). Clinical and economic evaluation of the use of fulvestrant compared with chemotherapy for the treatment of patients with locally progressive or metastatic ER (+) HER2 (-) breast cancer: Ukrainian realities. PharmacologyOnLine, 3, 355–366.
Rafalska, Y., & Kosyachenko, K. (2023). Analysis of pharmaceutical supply of breast cancer patients. ScienceRise: Pharmaceutical Science, 43(3), 87–94. https://doi.org/10.15587/2519-4852.2023.283490
Kizub, D. A., Naik, S., Abogan, A. A., Pain, D., Sammut, S. Shulman, L. N., & Martei, Y. M. (2022). Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda. Oncologist, 27(11), 958–970. https://pubmed.ncbi.nlm.nih.gov/36094141//
Baxi, S. M., Beall, R., Yang, J., & Mackey, T. K. (2019). A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Global Health, 15(57), 1–14. https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-019-0497-3
Fundytus, A., Sengar, M., Lombe, D., Hopman, W., Jalink, M. Gyawali, B., Trapani, D., Roitberg, F., De Vries, E. G. E., Moja, L., Ilbawi, A., Sullivan, R., & Booth, C. M. (2021). Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol., 22(10), 1367–1377. https://pubmed.ncbi.nlm.nih.gov/34560006/
Rurangwa, C., Ndayisenga, J., Sezirahiga, J., & Nyirimigabo, E. (2023). Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda. BMC Health Serv Res., 23(1), 717. https://pubmed.ncbi.nlm.nih.gov/37391753/
Li, W., Lu, W., Chen, H., Zhang, C., Wang, M., Zheng, F., Wu, H.-H., Wan, G.-W., Yang, Q., & Ye, L. (2024). Access to innovative anticancer medicines in China: a national survey on availability, price and affordability. BMJ Open, 14(4), e077089. https://bmjopen.bmj.com/content/14/4/e077089
Godman, B., Hill, A., Simoens, S., Selke, G., Selke, I., Krulichová, C., Diasi, Z., Martin, A. P., Oortwijnm, W., Timoneyb, A., Gustafssona, L. L., Voncina, L., Kwonb, H.-Y., Gulbinovicq, J., Gothamr, D., Wales, J., Cristina Da Silva, W., Bocheneku, T., Allocativ, E., . . . Hill, R. ( 2021). Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev. Pharmacoecon Outcomes Res., 21(4), 527–540. https://www.tandfonline.com/doi/epdf/10.1080/14737167.2021.1884546?needAccess=true
Molto, C., Hwang, T. J., Borrell, M., Andres, M., Gich, I., Barnadas, A., Amir, E., Kesselheim, A. S., & Tibau, A. (2020). Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer, 126(19), 4390–4399. https://pubmed.ncbi.nlm.nih.gov/32697362/
Vokinger, K. N., Hwang, T. J., Grischott, T., Reichert, S., Tibau, A., Rosemann, T., & Kesselheim, A. S. (2020). Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol., 21(5), 664–670. https://pubmed.ncbi.nlm.nih.gov/32359489/
Jenei, K., Raymakers, A. J. N., Bayle, A., Berger-Thürmel, K., Cherla, A., Honda, K., Jackson, C. G. A., Karikios, D., Trapani, D., Berry, S., & Gyawali, B. (2023). Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol., 24(6), 624–635. https://pubmed.ncbi.nlm.nih.gov/37269843/
Jenei, K., & Meyers, D. E. (2023). Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations. BMJ Open, 13(10), e066378. https://pmc.ncbi.nlm.nih.gov/articles/PMC10583055/
Postanova Kabinetu Ministriv Ukrainy “Deiaki pytannia realizatsii prohramy derzhavnykh harantii medychnoho obsluhovuvannia naselennia u 2025 rotsi” No. 1503 (2024, Hruden 24). https://zakon.rada.gov.ua/laws/show/1503-2024-%D0%BF#Text
Ukladeni dohovory pro medychne obsluhovuvannia naselennia za prohramoiu medychnykh harantii. Natsionalna sluzhba zdorovia Ukrainy. https://edata.e-health.gov.ua/e-data/dashboard/pmg-contracts
Uriad vyznachyv mekhanizm realizatsii Prohramy medychnykh harantii u 2025 rotsi. (2024, Hruden 30). Ministerstvo okhorony zdorovia Ukrainy. https://moz.gov.ua/uk/uryad-viznachiv-mehanizm-realizaciyi-programi-medichnih-garantij-u-2025-roci
DK 021:2015: 33150000-6 – Aparatura dlia radioterapii, mekhanoterapii, elektroterapii ta fizychnoi terapii (Systema liniinoho pryskoriuvacha). Prozzoro. https://prozorro.gov.ua/tender/UA-2023-05-24-015025-a
Li, L., Shan, T., Zhang, D., & Ma, F. (2024). Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study. J. Natl. Cancer. Cent, 4(3), 223–232. https://pubmed.ncbi.nlm.nih.gov/39281725/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
